Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H9NO6 |
Molecular Weight | 191.1388 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O
InChI
InChIKey=YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6985697http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttps://www.drugs.com/pro/sodium-nitroprusside.html |
https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803https://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675www.ncbi.nlm.nih.gov/pubmed/24071762Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6985697http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020845s016s017lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdfhttps://www.drugs.com/pro/sodium-nitroprusside.html |
https://www.ncbi.nlm.nih.gov/pubmed/7598246https://www.ncbi.nlm.nih.gov/pubmed/8644642 | https://www.ncbi.nlm.nih.gov/pubmed/7504768 | https://www.ncbi.nlm.nih.gov/pubmed/1724528 | https://adisinsight.springer.com/drugs/800001151https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19601018&CC=US&NR=2957021A&KC=A | https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20020124&CC=WO&NR=0205795A2&KC=A2https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/9845803https://www.ncbi.nlm.nih.gov/pubmed/19732062 | https://www.ncbi.nlm.nih.gov/pubmed/28988245 | https://www.ncbi.nlm.nih.gov/pubmed/24923291 | https://www.ncbi.nlm.nih.gov/pubmed/19563531http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019790s011lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021134s004lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675www.ncbi.nlm.nih.gov/pubmed/24071762
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/13106442
Pentaerythritol tetranitrate is an organic nitrate that has been used for the treatment of angina pectoris. Upon administration, the drug undergoes exstensive metabolism to NO which causes vasodilation and the relaxation of smooth muscle cells. The compound belongs to a familiy of explosive substances and may be used accordingly.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11396481https://www.ncbi.nlm.nih.gov/pubmed/15036360
Curator's Comment: NO can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively.
Originator
Sources: http://adisinsight.springer.com/drugs/800017960http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htmhttps://adisinsight.springer.com/drugs/800001151https://adisinsight.springer.com/drugs/800005482 | https://www.ncbi.nlm.nih.gov/pubmed/8839219https://www.ncbi.nlm.nih.gov/pubmed/22040938https://www.ncbi.nlm.nih.gov/pubmed/14848782
Curator's Comment: Was first prepared and studied by Junkmann in Germany, and has been suggested as a possible substitute for other nitrites and nitrates in the treatment of angina pectoris.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: liberation of NO Sources: http://www.ncbi.nlm.nih.gov/pubmed/2242448 |
|||
Target ID: CHEMBL2111348 Sources: www.ncbi.nlm.nih.gov/pubmed/18574453 |
0.1 µM [EC50] | ||
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804 |
|||
Target ID: CHEMBL1988 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12419094 |
|||
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10553632 |
|||
Target ID: CHEMBL2111348 |
|||
Target ID: CHEMBL2111348 Sources: https://www.google.com/patents/EP2805730A1 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NIPRIDE Approved UseSodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date1974 |
|||
Primary | NIPRIDE Approved UseSodium Nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with Sodium Nitroprusside can be minimized. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium Nitroprusside injection is also indicated for the treatment of acute congestive heart failure. Launch Date1974 |
|||
Palliative | INOMAX Approved UseINOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date1999 |
|||
Primary | DILATRATE-SR Approved Usedilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1998 |
|||
Primary | MONOKET Approved Usemonoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. Launch Date1993 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | NITROSTAT Approved UseAcute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date2000 |
|||
Primary | NITROGLYCERIN Approved UseManagement of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date1981 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date1981 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date1981 |
|||
Primary | Metamine Approved Usehttps://www.ncbi.nlm.nih.gov/pubmed/13426891 | https://www.ncbi.nlm.nih.gov/pubmed/13284675 |
|||
Primary | PERITRATE Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1151 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
557 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
356 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.7 pg/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14241 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6979 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2524 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2647 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.3 pg × min/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1458 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 min |
single, intravenous |
NITROPRUSSIDE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
120 mg 1 times / day steady-state, oral dose: 120 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7614524/ |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6713775/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOSORBIDE MONONITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
40 min |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8573222/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENTAERYTHRITOL DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
303 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24851040 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
ISOSORBIDE DINITRATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Other AEs: Headache, Dizziness... Other AEs: Headache (50%) Sources: Page: label/2005/020727lbl.pdf - p.13Dizziness (32%) Asthenia (14%) Nausea (10%) Bronchitis (8%) Hypotension (8%) Sinusitis (4%) Ventricular tachycardia (4%) Hyperglycemia (4%) Rhinitis (4%) Paresthesia (4%) Vomiting (4%) Amblyopia (3%) Hyperlipidemia (3%) Tachycardia (2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Disc. AE: Chest pain, Heart arrest... AEs leading to discontinuation/dose reduction: Chest pain (0.6%) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56Heart arrest (0.6%) Heart failure (0.6%) Hypotension (0.6%) Kidney failure (0.6%) Infection (0.4%) Ventricular fibrillation (0.4%) Dizziness (0.4%) Arrhythmia (0.2%) Cerebrovascular accident (0.2%) Syncope (0.2%) Gastroenteritis (0.2%) Myasthenia (0.2%) Dyspnea (0.2%) Edema lung (0.2%) Angioedema (0.2%) Breast carcinoma (0.2%) Uremia (0.2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Other AEs: Neurolysis, Ophthalmitis... Other AEs: Neurolysis (0.2%) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57Ophthalmitis (0.2%) Chest pain (6.4%) Heart failure (3.1%) Ventricular tachycardia (2.7%) Pneumonia (2.3%) Syncope (2.1%) Dyspnea (1.9%) Arrhythmia (1.7%) Hypotension (1.5%) Heart arrest (1.4%) Cerebrovascular accident (1.4%) Dizziness (1.4%) Cellulite (1.2%) Cerebral ischemia (1%) Coronary artery disease (1%) Anemia (1%) Bronchitis (1%) Dehydration (1%) Angina pectoris (1%) Hyperglycemia (1%) Hypoglycemia (1%) Infection (1%) Acute kidney failure (1%) Neoplasm (0.8%) Gout (0.8%) Atrial fibrillation (0.8%) Gastrointestinal hemorrhage (0.8%) Kidney failure (0.8%) Myocardial infarct (0.8%) Sepsis (0.6%) Asthma (0.6%) Accidental injury (0.6%) Cholecystitis (0.6%) Cholelithiasis (0.6%) Supraventricular tachycardia (0.6%) Esophagitis (0.4%) Edema lung (0.4%) Headache (0.4%) Osteomyelitis (0.4%) Peripheral vascular disease (0.4%) Bradycardia (0.4%) Digitalis intoxication (0.4%) Gastroenteritis (0.4%) Hyperkalemia (0.4%) Hemorrhage subarachnoid (0.4%) Deep thrombophlebitis (0.4%) Angioedema (0.4%) Ascites (0.4%) Infection (0.4%) Fibrillation ventricular (0.4%) Anomaly vascular (0.2%) Coagulation disorder (0.2%) Creatinine increased (0.2%) Hyponatremia (0.2%) Diarrhea (0.2%) Failure liver (0.2%) Neoplasm of the prostate (0.2%) Myasthenia (0.2%) Palpitations (0.2%) Urinary tract infection (0.2%) Dyspepsia (0.2%) Function kidney abnormal (0.2%) Anemia iron deficiency (0.2%) Alkalosis (0.2%) Arrhythmia nodal (0.2%) Arthralgia (0.2%) Breast carcinoma (0.2%) Hypokalemia (0.2%) Ketosis (0.2%) Cerebral infarct (0.2%) Emotional lability (0.2%) Edema face (0.2%) Gastritis hemorrhagic (0.2%) Abnormal gait (0.2%) Hematemesis (0.2%) Herpes zoster (0.2%) Uremia (0.2%) Leucopenia (0.2%) Thrombocytopenia (0.2%) Disorder parathyroid (0.2%) Disorder respiratory system (0.2%) Skin ulcer (0.2%) Abnormal thinking (0.2%) Vascular disorder NOS (0.2%) Wrist drop (0.2%) Gastritis (0.2%) |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Disc. AE: Asthenia, Headache... AEs leading to discontinuation/dose reduction: Asthenia (2.3%) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59Headache (7.4%) Dizziness (3.7%) Pain (0.8%) Chest pain (1.5%) Nausea (1.5%) Hypotension (1.4%) Abdominal pain (0.4%) Chills (0.4%) Kidney failure (0.4%) Malaise (0.4%) Heart arrest (0.6%) Confusion (0.4%) Diarrhea (0.4%) Gastroenteritis (0.2%) Back pain (0.2%) Acute kidney failure (0.2%) Myasthenia (0.2%) Nervousness (0.2%) Pruritus (0.2%) Heart failure (0.6%) Dyspepsia (0.2%) Cerebrovascular accident (0.2%) Constipation (0.2%) Dyspnea (0.2%) Vomiting (0.6%) Paresthesia (0.6%) Function kidney abnormal (0.4%) Palpitations (0.4%) Syncope (0.4%) Rash (0.6%) Rectal hemorrhage (0.4%) Ventricular fibrillation (0.4%) Angioedema (0.2%) Amblyopia (0.2%) Anorexia (0.2%) Neck pain (0.2%) Carcinoma (0.2%) Breast carcinoma (0.2%) Dehydration (0.2%) Edema face (0.2%) Edema peripheral (0.2%) Edema lung (0.2%) Fever (0.2%) Hyperglycemia (0.2%) Hypertension (0.2%) Infection (0.2%) Fungal infection (0.2%) Impotence (0.2%) Ketosis (0.2%) Breast neoplasm (0.2%) Lab test abnormal (0.2%) Myalgia (0.2%) Photophobia (0.2%) Pleural effusion (0.2%) Somnolence (0.2%) Sweaty (0.2%) Vasodilation (0.2%) Weight decrease (0.2%) Uremia (0.2%) |
240 mg 1 times / day steady, oral Highest studied dose Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, adult n = 312 Health Status: unhealthy Condition: chronic stable angina pectoris Age Group: adult Sex: unknown Population Size: 312 Sources: |
Other AEs: Headache... |
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: |
unhealthy, adult n = 267 Health Status: unhealthy Condition: chronic stable angina pectoris Age Group: adult Sex: unknown Population Size: 267 Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (6 patients) Sources: |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 159 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 159 Sources: |
Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (5%) Sources: Nausea (2%) |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 54 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 54 Sources: |
Disc. AE: Rash, Pruritus... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Pruritus (2%) |
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (4 patients) Sources: |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 1 patient) Sources: Vomiting (severe, 1 patient) Headache (severe, 1 patient) |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: |
Disc. AE: Hemodynamic test abnormal... AEs leading to discontinuation/dose reduction: Hemodynamic test abnormal (8 patients) Sources: |
0.6 mg/h 1 times / day multiple, transdermal Highest studied dose Dose: 0.6 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.6 mg/h, 1 times / day Sources: |
unhealthy, 51.4 ±4.3 years n = 11 Health Status: unhealthy Condition: menopausal hot flashes Age Group: 51.4 ±4.3 years Sex: F Population Size: 11 Sources: |
|
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Disc. AE: Pruritic rash, Erythema edematous... AEs leading to discontinuation/dose reduction: Pruritic rash (2 patients) Sources: Erythema edematous (2 patients) Vesicular eruption (2 patients) |
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: |
Other AEs: Methemoglobinemia... Other AEs: Methemoglobinemia (grade 5, 1 patient) Sources: |
0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Other AEs: Headache, Lightheadedness... Other AEs: Headache (63%) Sources: Lightheadedness (6%) Hypotension (4%) Syncope (4%) |
1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension Sources: |
5 ug/kg 1 times / day single, subcutaneous Dose: 5 ug/kg, 1 times / day Route: subcutaneous Route: single Dose: 5 ug/kg, 1 times / day Sources: |
unhealthy, pediatric n = 57 Health Status: unhealthy Age Group: pediatric Population Size: 57 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 10% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Asthenia | 14% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Tachycardia | 2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Amblyopia | 3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Hyperlipidemia | 3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Dizziness | 32% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Hyperglycemia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Paresthesia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Rhinitis | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Sinusitis | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Ventricular tachycardia | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Vomiting | 4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Headache | 50% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Bronchitis | 8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Hypotension | 8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: label/2005/020727lbl.pdf - p.13 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: label/2005/020727lbl.pdf - p.13 |
Angioedema | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Arrhythmia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Breast carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Cerebrovascular accident | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Dyspnea | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Edema lung | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Gastroenteritis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Myasthenia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Syncope | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Uremia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Dizziness | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Infection | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Ventricular fibrillation | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Chest pain | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Heart arrest | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Heart failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Hypotension | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Kidney failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.56 |
Abnormal gait | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Abnormal thinking | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Alkalosis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Anemia iron deficiency | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Anomaly vascular | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Arrhythmia nodal | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Arthralgia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Breast carcinoma | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cerebral infarct | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Coagulation disorder | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Creatinine increased | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Diarrhea | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Disorder parathyroid | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Disorder respiratory system | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Dyspepsia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Edema face | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Emotional lability | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Failure liver | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Function kidney abnormal | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Gastritis hemorrhagic | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Gastritis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hematemesis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Herpes zoster | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hypokalemia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hyponatremia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Ketosis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Leucopenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Myasthenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Neoplasm of the prostate | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Neurolysis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Ophthalmitis | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Palpitations | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Skin ulcer | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Thrombocytopenia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Uremia | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Urinary tract infection | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Vascular disorder NOS | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Wrist drop | 0.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Angioedema | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Ascites | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Bradycardia | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Deep thrombophlebitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Digitalis intoxication | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Edema lung | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Esophagitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Fibrillation ventricular | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Gastroenteritis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Headache | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hemorrhage subarachnoid | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hyperkalemia | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Infection | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Osteomyelitis | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Peripheral vascular disease | 0.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Accidental injury | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Asthma | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cholecystitis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cholelithiasis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Sepsis | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Supraventricular tachycardia | 0.6% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Atrial fibrillation | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Gastrointestinal hemorrhage | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Gout | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Kidney failure | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Myocardial infarct | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Neoplasm | 0.8% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Acute kidney failure | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Anemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Angina pectoris | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Bronchitis | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cerebral ischemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Coronary artery disease | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Dehydration | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hyperglycemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hypoglycemia | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Infection | 1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cellulite | 1.2% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Cerebrovascular accident | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Dizziness | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Heart arrest | 1.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Hypotension | 1.5% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Arrhythmia | 1.7% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Dyspnea | 1.9% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Syncope | 2.1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Pneumonia | 2.3% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Ventricular tachycardia | 2.7% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Heart failure | 3.1% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Chest pain | 6.4% | 75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.57 |
Acute kidney failure | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Amblyopia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Angioedema | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Anorexia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Back pain | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Breast carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Breast neoplasm | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Carcinoma | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Cerebrovascular accident | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Constipation | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Dehydration | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Dyspepsia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Dyspnea | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Edema face | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Edema lung | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Edema peripheral | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Fever | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Fungal infection | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Gastroenteritis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Hyperglycemia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Hypertension | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Impotence | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Infection | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Ketosis | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Lab test abnormal | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Myalgia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Myasthenia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Neck pain | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Nervousness | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Photophobia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Pleural effusion | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Pruritus | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Somnolence | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Sweaty | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Uremia | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Vasodilation | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Weight decrease | 0.2% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Abdominal pain | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Chills | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Confusion | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Diarrhea | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Function kidney abnormal | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Kidney failure | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Malaise | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Palpitations | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Rectal hemorrhage | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Syncope | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Ventricular fibrillation | 0.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Heart arrest | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Heart failure | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Paresthesia | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Rash | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Vomiting | 0.6% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Pain | 0.8% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Hypotension | 1.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Chest pain | 1.5% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Nausea | 1.5% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Asthenia | 2.3% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Dizziness | 3.7% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Headache | 7.4% Disc. AE |
75 mg 3 times / day multiple, oral Recommended|MTD Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Co-administed with:: isosorbide dinitrate(40 mg; 3/day) Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
unhealthy, mean age 57 years n = 517 Health Status: unhealthy Condition: heart failure Age Group: mean age 57 years Sex: M+F Population Size: 517 Sources: Page: nda/2005/020727_S000_Bidil_MedR.pdf - p.59 |
Headache | 57% | 240 mg 1 times / day steady, oral Highest studied dose Dose: 240 mg, 1 times / day Route: oral Route: steady Dose: 240 mg, 1 times / day Sources: |
unhealthy, adult n = 312 Health Status: unhealthy Condition: chronic stable angina pectoris Age Group: adult Sex: unknown Population Size: 312 Sources: |
Headache | 6 patients Disc. AE |
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: |
unhealthy, adult n = 267 Health Status: unhealthy Condition: chronic stable angina pectoris Age Group: adult Sex: unknown Population Size: 267 Sources: |
Nausea | 2% Disc. AE |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 159 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 159 Sources: |
Headache | 5% Disc. AE |
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult n = 159 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 159 Sources: |
Pruritus | 2% Disc. AE |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 54 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 54 Sources: |
Rash | 2% Disc. AE |
5 mg 1 times / day steady, oral Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: |
unhealthy, adult n = 54 Health Status: unhealthy Condition: myocardial infarction or congestive heart failure Age Group: adult Sex: unknown Population Size: 54 Sources: |
Hypotension | 4 patients Disc. AE |
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: |
Headache | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Nausea | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Vomiting | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Hemodynamic test abnormal | 8 patients Disc. AE |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: |
Erythema edematous | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Pruritic rash | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Vesicular eruption | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Methemoglobinemia | grade 5, 1 patient | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: |
Hypotension | 4% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Syncope | 4% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Lightheadedness | 6% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Headache | 63% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Hypotension | Disc. AE | 1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Page: abstract |
no | |||
Sources: https://link.springer.com/article/10.1007/BF00497774 Page: abstract |
yes | |||
Page: abstract |
yes | |||
Page: abstract |
yes | |||
Sources: https://www.nature.com/articles/aps201225 Page: abstract |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no |
PubMed
Title | Date | PubMed |
---|---|---|
[The classic anti-anginal agents and molsidomine]. | 1983 Feb |
|
Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy. | 1998 Dec |
|
Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. | 1998 Oct |
|
Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. | 1999 Apr |
|
Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. | 1999 Apr |
|
Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. | 1999 Jun |
|
Nitric oxide prevents anoxia-induced apoptosis in colonic HT29 cells. | 1999 Jun 15 |
|
The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administration. | 1999 Mar |
|
The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. | 1999 Mar |
|
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. | 1999 Nov 15 |
|
Nitric oxide inhalation inhibits pulmonary apoptosis but not inflammatory injury in porcine meconium aspiration. | 1999 Oct |
|
Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. | 1999 Sep |
|
Nitric oxide stimulates ACTH secretion and the transcription of the genes encoding for NGFI-B, corticotropin-releasing factor, corticotropin-releasing factor receptor type 1, and vasopressin in the hypothalamus of the intact rat. | 1999 Sep 1 |
|
The potential role of nitric oxide in the hypertrophic growth of the left ventricle. | 2000 |
|
Nitric oxide-compromised hypertension: facts and enigmas. | 2000 |
|
Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. | 2000 |
|
Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. | 2000 Dec |
|
Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway. | 2000 Feb |
|
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury. | 2000 Jan |
|
Metallothionein-III prevents glutamate and nitric oxide neurotoxicity in primary cultures of cerebellar neurons. | 2000 Jul |
|
Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. | 2000 May 1 |
|
The neurogenic vasodilator response to endothelin-1: a study in human skin in vivo. | 2000 Nov |
|
Inhibition of nitric oxide synthase enhances the myocardial toxicity of phenylpropanolamine. | 2000 Nov |
|
A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina. | 2001 |
|
Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. | 2001 Apr |
|
Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. | 2001 Aug 17 |
|
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. | 2001 Feb |
|
Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide-treated rats. | 2001 Mar 23 |
|
Nitric oxide and chronic HCV and HIV infections. | 2001 May |
|
[Quality of life and angina pectoris. Comparison of the effects of 2 nitrate derivatives administered discontinuously: transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day)]. | 2001 Oct |
|
[Anti-ischemic efficacy of sustained-release isosorbide-5-mononitrate: echocardiography during mental and physical stress]. | 2001 Oct |
|
[Antianginal and anti-ischemic effects of Mono Mac 50D preparation as an agent in combined treatment of patients with stable angina]. | 2002 |
|
[The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome]. | 2002 |
|
Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers. | 2002 |
|
Nitric oxide induced cervical ripening in the human: Involvement of cyclic guanosine monophosphate, prostaglandin F(2 alpha), and prostaglandin E(2). | 2002 Apr |
|
Massive choroidal hemorrhage associated with low molecular weight heparin therapy. | 2002 Apr |
|
Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). | 2002 Jan |
|
[Effect of isosorbide mononitrate on hypotensive action of enalapril in patients with mild and moderate hypertension]. | 2002 Jul |
|
Direct injection of aqueous samples in packed column supercritical fluid chromatography of isosorbide-5-mononitrate from drug release testing. | 2002 Jun 20 |
|
Sudden death under successful medical management of sick sinus syndrome after cardiac pacing discontinuation. | 2002 Oct |
|
A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations. | 2002 Oct 15 |
|
Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. | 2002 Sep |
|
Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis. | 2002 Sep-Oct |
|
Simultaneous determination of aspirin and isosorbide 5-mononitrate in formulation by reversed phase high pressure liquid chromatography. | 2003 Aug 21 |
|
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. | 2003 Feb |
|
Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial. | 2003 Jul |
|
Prevention of variceal rebleeding. | 2003 Mar 15 |
|
Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. | 2003 Mar 7 |
|
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. | 2011 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16644612
twice-daily 8-mg tablet
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6199592
Curator's Comment: In epithelial cells, NO increased apoptosis by 2.1 +/- 0.2-fold, augmented mRNA expression of Bax, and reduced expression of Bcl-2 compared with basal cultures. In stromal cells, NO increased cell proliferation in a dose-dependent manner, an effect that was blocked by a NO synthase inhibitor.
Was studied the action of the biologically active metabolite of molsidomine, N-morpholino-N-nitrosoamino-acetonitrile (SIN), on eicosanoid formation and functional behavior of bovine coronary arteries and human platelets in vitro. Molsidomine itself was inactive
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000009909
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
WHO-ATC |
C01DA14
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NDF-RT |
N0000175415
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
||
|
WHO-VATC |
QC01DA14
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
240-197-2
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
Z-57
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
6062
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
1353102
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
28004
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
758619
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
100000090392
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
5177
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
LX1OH63030
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
m6541
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB08336MIG
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
LX1OH63030
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
C030397
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
SUB30087
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
27661
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
C47575
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
DB01020
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
1506
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
ISOSORBIDE MONONITRATE
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
DTXSID9023176
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
16051-77-7
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
SUB12087MIG
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
ALTERNATIVE | |||
|
CHEMBL1311
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY | |||
|
7052
Created by
admin on Fri Dec 15 15:23:16 GMT 2023 , Edited by admin on Fri Dec 15 15:23:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD